Biotech | October 22, 2021
WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
A veteran in cell therapy and oncology commercialisation
Drug formulations and biologics make impressive gains
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
